Today: 13 November 2025
Subscribe
Browse Category

Analyst Ratings News 3 October 2025 - 21 October 2025

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside. Beam’s stock jumped sharply after the FDA awarded priority designations to its gene-editing therapies. On Oct 20,
21 October 2025
 ·  ·  ·  ·  · 
SoFi’s Roller-Coaster Rally: Fintech Stock Soars 230% in 2025 – What’s Next for SOFI?

SoFi Stock Surges on Analyst Upgrade and $1.6 Trillion Fintech Opportunity

Stock Rebound After Volatile Weeks SoFi’s stock has been on a roller-coaster. After tripling in the past year, climbing from single-digit prices to a record ~$30 in late September, the fintech favorite hit turbulence ts2.tech. In the final weeks of September and into early October, profit-taking and broader market jitters knocked SOFI off its highs. The shares slid about 10–15% from their peak, even logging a 5% one-day drop on Oct. 16 to around $26.60 ts2.tech. “Most buyers are already in,” one analyst quipped during the pullback – cautioning that the pool of new investors willing to propel the stock
20 October 2025
 ·  ·  ·  ·  · 
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Stock Jumps as Outlook Brightens Gilead’s share price has been on a tear in recent weeks, reaching new highs for 2025. By mid-day October 17, GILD was up about 4.7% to roughly $123 per share benzinga.com. Year-to-date, the stock has rallied nearly 47%, adding tens of billions to Gilead’s market value stockanalysis.com. This far outpaces the single-digit gain of the Nasdaq Biotechnology Index over the same period stockanalysis.com invesco.com. Investors have cheered a string of positive catalysts: strong earnings, a fortified HIV franchise, and growing pipeline prospects. Notably, Gilead’s Q2 results in August beat expectations and prompted management to raise
17 October 2025
 ·  ·  ·  · 
Broadcom’s $10B AI Chip Deal Ignites Stock Surge – What’s Powering This Tech Giant’s Boom

Broadcom (AVGO) Stock Soars After $10B OpenAI AI Chip Deal – Analysts Raise Targets

Stock Performance and Recent Movement Broadcom’s stock has surged dramatically in 2023–2025, fueled by the AI boom and strategic deals ts2.tech. After a 10-for-1 split in Feb 2024, retail interest surged along with its fundamentals ts2.tech. By Oct 2025, Broadcom’s market cap surpassed $1.5 trillion ts2.tech. The share price peaked around $374 in early Sept 2025 (post-split), roughly double its level a year prior ts2.tech. Even after an early-October dip (amid broader market volatility), AVGO remains up ~70% YTD ts2.tech, far outperforming the S&P 500. Over the past week, the stock was volatile. On Oct 13 AVGO jumped +9.9% investing.com following
17 October 2025
 ·  ·  ·  ·  · 
Lockheed Martin News Roundup (Oct 1–10, 2025): Defense Giant Navigates New Contracts, Space Ambitions, and Market Momentum

Lockheed Martin (LMT) Stock Rises on $11B Navy Contract, Dividend Hike & Analyst Upgrades

Stock Performance Today and Recent Trend Lockheed’s stock opened around $504.8 on Oct. 15, 2025 and is roughly flat on the day marketbeat.com. Over the past week it has seen minor fluctuation but remains in a broad trading range. After falling as low as ~$410 in mid-July (post-Q2 earnings), LMT has rebounded over 20% and is now about 18% below its 52-week high benzinga.com marketbeat.com. Volume remains healthy and trading above its 50-day/200-day averages, reflecting continued investor interest. Despite some recent volatility, analysts note that LMT has strong governmental support. “Lockheed Martin makes 97% of its revenue from the U.S.
15 October 2025
 ·  ·  ·  ·  · 
Canadian Solar (CSIQ) Stock Skyrockets: Analyst Upgrade & Battery Boom Ignite Rally

Canadian Solar (CSIQ) Stock Skyrockets: Analyst Upgrade & Battery Boom Ignite Rally

Stock Rally and Analyst Buzz Canadian Solar’s stock has surged sharply this week. On Oct 14 its share price hit a 52-week high of around $16.00 before closing at $15.72 marketbeat.com. This spike was driven by two main headlines: Goldman Sachs unexpectedly raised its CSIQ price target on Oct 9 (boosting investor confidence, even as Goldman still left a “sell” rating marketbeat.com), and news out of China about planned cuts to solar panel capacity (seen as reducing supply gluts). Indeed, Reuters reports that Chinese regulators may soon clamp down on excess PV manufacturing, which sent Chinese solar stocks soaring on
15 October 2025
 ·  ·  ·  ·  · 
PNC Financial Stock Oversold – Q3 Earnings Beat & Analyst Upgrades Fuel Rebound Hopes

PNC Financial Stock Oversold – Q3 Earnings Beat & Analyst Upgrades Fuel Rebound Hopes

Current Stock Performance & Technical Signals As of mid-October 2025, PNC stock is trading around the $190 level, having recovered from a brief dip into the mid-$180s. The share price is roughly 3.5% lower over the past quarter and basically flat compared to a year ago investing.com, underperforming the S&P 500 during that span. The stock is about 12% below its 50-day moving average (~$198), reflecting recent weakness, but remains above its 200-day moving average (~$183) – a sign it’s still in a longer-term uptrend off last year’s lows. PNC’s 52-week trading range spans $145.12 to $216.26, so at ~$190
15 October 2025
 ·  ·  ·  ·  · 
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

Current Stock Price and Performance (Oct 8 2025) UnitedHealth Group’s share price has been volatile in 2025. On 8 Oct 2025 the stock closed around $372—IndMoney quoted $372.93 while Investing.com listed $372.64 indmoney.com investing.com. Reuters reported that the last trade was $371.46, up 2.15 % from the previous day reuters.com. The wide 52‑week range ($234.60‑$630.73) highlights the enormous drawdown from April’s peak and underscores the severity of the 2025 sell‑off. The stock’s average daily trading volume is about 5.9 million shares, and its beta of 0.47 indicates less volatility than the S&P 500 reuters.com marketbeat.com. Year‑to‑date performance remains negative (‑28 % to ‑37 % depending on the reference period),
8 October 2025
 ·  ·  ·  ·  · 
PLUG Stock’s 48-Hour Whirlwind: ‘Street‑High’ $4 Target, Oppenheimer’s “first recovery step,” and a hydrogen‑sector reality check (Sept. 25–26, 2025)

Plug Power Stock Explodes 170% After Bold Analyst Upgrade – Short Squeeze Fuels Hydrogen Hype

Analyst Upgrade Triggers Price Surge Plug Power’s stock price skyrocketed after a bold analyst upgrade sparked a wave of buying. On Friday (Oct 3), Plug Power shares spiked 34.6% in a single session to about $3.80 – a huge jump that sent the stock to a new 52-week high finanzen.net. The rally was fueled by news that investment bank H.C. Wainwright had issued an extremely bullish call: analyst Amit Dayal not only reaffirmed his Buy rating on Plug Power, but also more than doubled his price target from $3 to $7 finanzen.net. This $7 target is now the highest on
6 October 2025
 ·  ·  ·  ·  ·  · 
Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast’s stock has surged recently on the Ryoncil news. At the Oct 2 close it stood at $17.02 – up +4.6% on the day and roughly +8% from two weeks prior stockinvest.us marketbeat.com. This rally follows last week’s announcements: on Sept 26 the company announced its therapies are U.S.-origin and exempt from tariffs nasdaq.com, and on Oct 2 it disclosed that CMS has made the HCPCS J‐Code for Ryoncil (J3402) permanent starting Oct 1 stocktitan.net. CEO Silviu Itescu called the new J-code “a critical element for successful commercialization of rare disease products, ensuring more efficient billing and enabling timely access
3 October 2025
 ·  ·  ·  ·  ·  · 
1 2
Go toTop